SCHEMBL23980835

SCHEMBL23980835

Fc1cc(Cl)ccc1C1COc2c(Br)cccc2N1

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 1/20 0.37
HTR2C P28335 1/20 0.37
HTR2B P41595 1/20 0.37
AR P10275 1/20 0.33
NPC1 O15118 1/20 0.32
HPGD P15428 1/20 0.32
RAB9A P51151 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
GRM2 Q14416 1/20 0.32
PRKAB2 O43741 1/20 0.31
PRKAG1 P54619 1/20 0.31
PRKAA2 P54646 1/20 0.31
PRKAA1 Q13131 1/20 0.31
PRKAG3 Q9UGI9 1/20 0.31
PRKAG2 Q9UGJ0 1/20 0.31
PRKAB1 Q9Y478 1/20 0.31
RORC P51449 1/20 0.31
OPRL1 P41146 2/20 0.31
CYP3A4 P08684 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30217450 1.00 HTR2A (0.37) HTR2AHTR2CHTR2BARNPC1
SCHEMBL2380145 0.81 MEN1 (0.42) HTR2AHTR2CHTR2BARHPGD
SCHEMBL30275367 0.74 CYP11B1 (0.39) HTR2AHTR2CHTR2BNPC1HPGD
SCHEMBL23980935 0.74 CYP11B1 (0.39) HTR2AHTR2CHTR2BNPC1HPGD
SCHEMBL2378790 0.73 AR (0.46) ARNPC1SMN1; SMN2
SCHEMBL23980833 0.72 HTR2A (0.37) HTR2AHTR2CHTR2BNPC1HPGD
SCHEMBL24186456 0.72 HTR2A (0.37) HTR2AHTR2CHTR2BNPC1HPGD
SCHEMBL29924349 0.72 HTR2A (0.37) HTR2AHTR2CHTR2BNPC1HPGD
SCHEMBL30232635 0.71 HTR2A (0.38) HTR2AHTR2CHTR2BSMN1; SMN2PRKAB2
SCHEMBL2377614 0.71 AR (0.33) AR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12552791-B2 Heterocyclic GLP-1 agonists GASHERBRUM BIO, INC. (US) 2026-02-17 US disclosed
EP-4143183-B1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO INC (US) 2025-10-22 EP disclosed
US-20250214999-A1 HETEROCYCLIC GLP-1 AGONISTS SHOUTI INC. 2025-07-03 US disclosed
US-20230295154-A1 HETEROCYCLIC GLP-1 AGONISTS SHOUTI INC. 2023-09-21 US disclosed
US-20230295154-A1 HETEROCYCLIC GLP-1 AGONISTS SHOUTI INC. 2023-09-21 US disclosed
US-20230295154-A1 HETEROCYCLIC GLP-1 AGONISTS SHOUTI INC. 2023-09-21 US disclosed
CN-115667250-A Heterocyclic GLP-1 agonists 加舒布鲁姆生物公司 2023-01-31 CN disclosed
WO-2021219019-A1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO, INC. (US) 2021-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295154-A1 HETEROCYCLIC GLP-1 AGONISTS GLP1R, GIPR, GCGR HTR2A 181/4885HTR2C 160/4885HTR2B 206/4885
US-12552791-B2 Heterocyclic GLP-1 agonists GLP1R, NPY1R, NPY2R HTR2A 436/4885HTR2C 191/4885HTR2B 418/4885
US-20250214999-A1 HETEROCYCLIC GLP-1 AGONISTS GLP1R, GIPR, GCGR HTR2A 181/4885HTR2C 160/4885HTR2B 206/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.